Frontier Biotechnologies and GSK sign billion dollar deal for kidney disease treatments
Frontier Biotechnologies and GSK have partnered on kidney disease therapies. The deal grants GSK global rights and is worth up to one billion dollars.
Insights:
Frontier Biotechnologies announced today, February 24, 2026, that it has granted GSK plc , headquartered in the United Kingdom 
GB, worldwide rights to develop and commercialize two small interfering RNA (siRNA) therapies targeting kidney diseases. The licensing agreement, which could be worth up to $1 billion, transfers full development and commercialization responsibility for the programs to the major drugmaker.
GB, worldwide rights to develop and commercialize two small interfering RNA (siRNA) therapies targeting kidney diseases. The licensing agreement, which could be worth up to $1 billion, transfers full development and commercialization responsibility for the programs to the major drugmaker.Under the terms of the announced deal, GSK assumes the worldwide rights for the development and commercialization of the two siRNA therapies. This strategic reallocation of responsibility allows the larger pharmaceutical firm to lead the progression of these kidney-focused programs. The transaction represents a significant financial commitment at scale, with the potential total value reaching the $1 billion mark.
